Oncolytics Biotech Inc.
4660 La Jolla Village Drive
Suite 850
San Diego
CA
92122
United States
Website: http://www.oncolyticsbiotech.com/
447 articles with Oncolytics Biotech Inc.
-
Top 6 Biotech Stocks of 2017
12/20/2017
When considering options in the biotech sector, experts often look more into the major companies providing massive amounts of resources to new candidates. -
Acerus Appoints Mr. Mark Lievonen to Its Board of Directors
12/7/2017
The appointment fills the vacancy resulting from Mr. Tom Rossi’s resignation from the Board of Directors.
-
Oncolytics Biotech Receives Favorable Final Advice Letter from the European Medicines Agency for REOLYSIN in Metastatic Breast Cancer
12/5/2017
The Letter refers to the proposed use of pelareorep in combination with paclitaxel, for the treatment of hormone receptor positive, HER2 receptor negative metastatic breast cancer patients in a pivotal phase 3 registration study.
-
Oncolytics Biotech Establishes Scientific Advisory Board Focused on REOLYSIN Registration Study in Metastatic Breast Cancer
11/30/2017
The SAB will provide Oncolytics with significant clinical expertise and experience in breast cancer drug development in both the U.S. and Europe.
-
Under the terms of The Agreement, Adlai will have exclusive development and commercialization rights to REOLYSIN in China, Hong Kong, Macau, Singapore, South Korea and Taiwan.
-
Oncolytics Biotech Announces 2017 Third Quarter Results
11/8/2017
Oncolytics Biotech today announced its financial results and operational highlights for the quarter ended September 30, 2017.
-
Oncolytics Biotech Appoints Deborah Brown to Board of Directors
11/2/2017
"Ms. Brown's wealth of experience in new product launches and market expansion will lend valuable insights as we progress REOLYSIN toward commercialization," said Dr. Matt Coffey, President and CEO of Oncolytics Biotech.
-
Oncolytics Biotech Announces Successful End-Of-Phase II Meeting With FDA For REOLYSIN In Metastatic Breast Cancer
9/18/2017
-
Oncolytics Biotech Announces First Patient Treated In MUK Eleven Study
9/14/2017
-
Oncolytics Biotech Announces The Presentation Of REOLYSIN Clinical Data At ESMO 2017 Congress
9/11/2017
-
Oncolytics Biotech Announces 2017 Second Quarter Results
8/3/2017
-
Oncolytics Biotech To Present REOLYSIN Safety Data In Combination With Chemotherapy At ESMO 2017 Congress
7/26/2017
-
Oncolytics Biotech Appoints Andrew De Guttadauro, President Of Oncolytics Biotech (U.S.) Inc.
6/29/2017
-
Oncolytics Biotech Opens U.S. Based Office In San Diego
6/27/2017
-
Oncolytics Biotech Announces Closing Of Public Offering Of Units
6/1/2017
-
Oncolytics Biotech Prices Public Offering Of Units
5/24/2017
-
Oncolytics Biotech Announces Proposed Public Offering
5/24/2017
-
Oncolytics Biotech Announces Participation In World Immunotherapy Congress USA 2017
5/23/2017
-
Oncolytics Biotech Announces FDA Fast Track Designation For REOLYSIN In Metastatic Breast Cancer
5/8/2017
-
Oncolytics Biotech Announces Voting Results From Its Annual Meeting Of Shareholders
5/5/2017